Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Parental Bacillus Calmette-Guérin vaccine scars decrease infant mortality in the first six weeks of life: A retrospective cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Treatment patterns in patients with treatment-resistant depression in Danish patients with major depressive disorder

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. On the investigation of non-specific effects of BCG: Interpreting global vaccine data

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The tuberculosis vaccine Bacillus Calmette-Guérin trains the innate immune system

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  • M. L.T. Berendsen
  • F. Schaltz-Buchholzer
  • P. Bles
  • S. Biering-Sørensen
  • K. J. Jensen
  • I. Monteiro
  • I. Silva
  • P. Aaby
  • C. S. Benn
Vis graf over relationer

Background: Live attenuated vaccines have been observed to have particularly beneficial effects for child survival when given in the presence of maternally transferred immunity (priming). We aimed to test this finding and furthermore explore the role of paternal priming. Methods: In an exploratory, retrospective cohort study in 2017, parental Bacillus Calmette-Guérin (BCG) scars were assessed for infants from the Bandim Health Project (BHP) who had participated in a 2008–2013 trial of neonatal BCG vaccination. Parental scar effects on mortality were estimated from birth to 42 days, the age of the scheduled diphtheria-tetanus-pertussis (DTP) vaccination, in Cox proportional hazard models adjusted with Inverse Probability of Treatment Weighting. Findings: For 66% (510/772) of main trial infants that were still registered in the BHP area, at least one parent was located. BCG scar prevalence was 77% (353/461) among mothers and 63% (137/219) among fathers. In the first six weeks of life, maternal scars were associated with a mortality reduction of 60% (95%CI, 4% to 83%) and paternal scars with 49% (-68% to 84%). The maternal scar association was most beneficial among infants that had received BCG vaccination at birth (73% (-1% to 93%)). Although priming was less evident for paternal scars, having two parents with scars reduced mortality by 89% (13% to 99%) compared with either one or none of the parents having a scar. Interpretation: Parental BCG scars were associated with strongly increased early-life survival. These findings underline the importance of future studies into the subject of inherited non-specific immunity and parental priming. Funding: Danish National Research Foundation; European Research Council; Novo Nordisk Foundation; University of Southern Denmark.

OriginalsprogEngelsk
Artikelnummer101049
TidsskriftEClinicalMedicine
Vol/bind39
Sider (fra-til)101049
ISSN2589-5370
DOI
StatusUdgivet - sep. 2021

Bibliografisk note

Funding Information:
This work was supported by the Danish National Research Foundation (grant DNRF108 to the Research Center for Vitamins & Vaccines); the European Research Council (ERC Starting grant [# 243149 ] to CSB; the Novo Nordisk Foundation (research professorship grant to PA) and the University of Southern Denmark (SDU faculty scholarships that funded MLTB and FSB).

Funding Information:
MLTB and FSB received support from the University of Southern Denmark in the form of a scholarship. CSB holds an ERC starting grant and PA holds a research professorship from Novo Nordisk. PB, SBS, KJJ, IM, and IS declare no conflict of interest.

Publisher Copyright:
© 2021 The Authors

ID: 75348358